Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study

por Dauvilliers, Yves, Arnulf, Isabelle, Szakacs, Zoltan, Leu-Semenescu, Smaranda, Lecomte, Isabelle, Scart-Gres, Catherine, Lecomte, Jeanne-Marie, Schwartz, Jean-Charles
Publicado 2019

Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies

por Ligneau, Xavier, Shah, Rashmi R, Berrebi‐Bertrand, Isabelle, Mirams, Gary R, Robert, Philippe, Landais, Laurent, Maison‐Blanche, Pierre, Faivre, Jean‐François, Lecomte, Jeanne‐Marie, Schwartz, Jean‐Charles
Publicado 2017

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol

por Krief, Stéphane, Berrebi‐Bertrand, Isabelle, Nagmar, Isabelle, Giret, Martin, Belliard, Simon, Perrin, David, Uguen, Marilyne, Robert, Philippe, Lecomte, Jeanne‐Marie, Schwartz, Jean‐Charles, Finance, Olivier, Ligneau, Xavier
Publicado 2021

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial

por Dauvilliers, Yves, Verbraecken, Johan, Partinen, Markku, Hedner, Jan, Saaresranta, Tarja, Georgiev, Ognian, Tiholov, Rumen, Lecomte, Isabelle, Tamisier, Renaud, Lévy, Patrick, Scart-Gres, Catherine, Lecomte, Jeanne-Marie, Schwartz, Jean-Charles
Publicado 2020